Evan Lindberg's battle with neuroblastoma highlights the challenges in treating childhood cancers, which often have limited treatment options and devastating outcomes. Despite decades of research by experts like Dr. Yael Mossé, progress remains slow in developing targeted therapies for these cancers, contributing to their high mortality rates. With only a few drugs approved for children since 2000, there's a significant need for advancements. One promising area includes PROTACs, which harness the cell's protein disposal mechanisms, offering hope for new treatment avenues that could improve outcomes for young patients.
"For four years, my son never had a day off... frequently recovery was worse than the treatment." - Gavin Lindberg, father of neuroblastoma patient.
"We really have made very little progress in developing more rational or targeted therapies" - Yael Mossé, paediatric oncologist on neuroblastoma treatment.
PROTACs eliminate the protein altogether by tethering disease-associated proteins to an enzyme that tags the protein for destruction.
These childhood cancers differ from adult ones in their biology, and thus require distinct treatments, yet few drugs are specifically for children.
Collection
[
|
...
]